FGFR2 and infantile convulsions and choreoathetosis: Among actionable targets, isocitrate dehydrogenase (IDH) 1 and 2 and fibroblast growth factor receptor (FGFR) 2 alterations have gained increased clinical interest and recently the FGFR inhibitors Pemigatinib, Infigratinib and Futibatinib have been approved as the first targeted therapies in advanced iCCA patients with FGFR2 fusions or rearrangements9–11.